Private Market View

PharmaVision ( korea )

Suwon, South Korea · Founded 2020 · Privately Held (backing)

Last price · $/share
Implied valuation
Total raised
Last round

Key facts

  • Notable investors include Oregon Angel Partners.
  • Status: Privately Held (backing).
Free account
See the evidence behind this price
  • ·The complete investor list — 1 names
  • ·Watchlist + deal alerts for PharmaVision ( korea )
  • ·The full record, as it builds
Create free account
No card required

Funding rounds

No rounds on record

No funding rounds for PharmaVision ( korea ) are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.

Pro members can request priority coverage with a 48-hour turnaround.

About PharmaVision ( korea )

Provider of pharmaceutical formulation development and regulatory approval services intended to support the healthcare sector. The company offers drug formulation, product development, and regulatory filing services, enabling pharmaceutical and biotechnology companies to bring their drug products through the development and approval process.

Sector
Healthcare
HQ
Suwon, South Korea
Founded
2020
Ownership
Privately Held (backing)
PA Mark — not yet priced

PharmaVision ( korea ) doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.

Pro members can request priority coverage with a 48-hour turnaround.

Recorded secondary trades

No prints on record

No secondary trades in PharmaVision ( korea ) shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.

Pro members can request priority coverage with a 48-hour turnaround.

Institutional fund marks

No fund marks yet

No SEC-registered fund has reported a fair-value mark on PharmaVision ( korea ) in its N-PORT filings yet. We sweep new filings monthly.

Pro members can request priority coverage with a 48-hour turnaround.